SCHEDULE: Rock Springs Capital Exits Spruce Biosciences Stake

Sentiment:

Beneficial Ownership Amendment 13 August 2025 4:31 PM

📋All filings for Spruce Biosciences, INC

Rock Springs Capital and its affiliates have reported a complete divestment of their beneficial ownership in Spruce Biosciences, Inc.

Worse than expectedA significant institutional investor, Rock Springs Capital, has fully exited its position in Spruce Biosciences, Inc. Reducing ownership to 0% from a previously held stake is generally viewed as a negative signal by the market, suggesting a lack of confidence or a shift away from the company's prospects.

Summary

Rock Springs Capital Management LP, Rock Springs Capital LLC, Rock Springs Capital Master Fund LP, Mark Bussard, and Kris Jenner (collectively, the "Reporting Persons") have filed an Amendment No. 5 to Schedule 13G.
The filing indicates that as of July 3, 2025, the Reporting Persons beneficially own 0 shares of Spruce Biosciences, Inc. Common Stock.
This represents 0% of the class of securities, signifying a complete divestment of their previous holdings.
The shares were not acquired or held for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 3

Explanation: The sentiment is moderately negative as a significant institutional investor has completely divested its stake, which can be interpreted by the market as a loss of confidence in the company's future performance or valuation.

Negatives

Rock Springs Capital, a significant institutional investor, has fully divested its stake in Spruce Biosciences, Inc., reducing its beneficial ownership to 0%.

Risks

The complete divestment by a notable institutional investor like Rock Springs Capital could be perceived negatively by the market, potentially leading to decreased investor confidence.
A reduction in institutional ownership might reduce liquidity or increase volatility for Spruce Biosciences' stock.

Future Outlook

This filing does not contain any forward-looking statements or guidance from Spruce Biosciences, Inc. regarding its future operations or financial performance.

Industry Context

This filing reflects a change in an institutional investor's portfolio allocation rather than a direct operational or strategic update from Spruce Biosciences. Such divestments can occur due to various factors, including portfolio rebalancing, changes in investment strategy, or a reassessment of the issuer's prospects relative to industry peers.

Stakeholder Impact

Shareholders may react negatively to the news of a major institutional investor exiting its position, potentially leading to downward pressure on the stock price.
Potential investors might view this divestment as a cautionary signal, influencing their investment decisions regarding Spruce Biosciences.

Key Dates

Date	Description
07/03/2025	Date of event which required the filing of this statement, indicating the point at which beneficial ownership dropped to 0%.
08/13/2025	Date the Schedule 13G/A filing was signed by the Reporting Persons.

Recommendation

hold

While a major investor exiting is a negative signal, this filing alone does not provide sufficient fundamental information about Spruce Biosciences' operations or financials to warrant a 'sell' recommendation. Investors should 'hold' and await further operational updates or financial reports from the company to assess the underlying reasons for this divestment and its potential impact.

Keywords

Spruce Biosciences, Rock Springs Capital, Schedule 13G, Beneficial Ownership, Institutional Investor, Divestment, Common Stock, SEC Filing

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.